Compass Therapeutics Investor Presentation Deck

Key 12 Month Milestones COMPASS THERAPEUTICS COMPASS THERAPEUTICS Q4 2022 Initiated CTX-009 US CRC Phase 2 Study Q4 2022 Completed the ongoing CTX-471 Phase 1b study ↑ Q1 2023 Initiating CTX-009 US BTC Phase 2/3 Study Q4 2022 Initiated CTX-471 plus PD-1 Study H1 2023 CTX-8371 IND filing H2 2023 Top line data from CTX-009 US CRC Phase 2 Study H2 2023 Initiate CTX-009 U.S. Ovarian /other Phase 2 Study 9 H1 2024 Top line data from CTX-009 US Phase 2/3 BTC Study H2 2023 Initiaite CTX-8371 Phase 1 Study 40

View entire presentation